LifeSignals’ LX1550 Multiparameter Remote Monitoring Platform has been granted FDA Class II 510 (K) approval, following recent CE marketing. With the Remote Monitoring Platform, healthtech companies can improve their product and service portfolios and provide essential vital sign monitoring regardless of patient location. The Platform features a wearable multiparameter biosensor that can track electrocardiography (2-channel ECG), heart and respiration rate, skin temperature and body posture readings. The encrypted data can then be transmitted to a relay app with cloud-based technology from which healthcare professionals can access the data. LifeSignal’s Founder and CEO, Surendar Magar, stated that, “This FDA 510 (k) approval marks another major milestone in the company’s development and mission,” and that, “COVID-19 has broken down the barriers to remote patient monitoring globally”.

Read more here.

More on: